Hilda L. Chan

This study identifies an early neutrophil interferon program that predicts resistance to anti-PD1 therapy and limits durable anti-tumor immunity.

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

The paper analyzes bone metastases from six cancer types using single-cell RNA-seq to identify three immune archetypes and their mechanisms of bone colonization.

CBP/P300 BRD inhibition reduces neutrophil accumulation and enhances antitumor immunity in neutrophil-enriched TNBC, improving responses to standard therapies.